重组产气荚膜梭菌β毒素突变体的表达与免疫保护性分析

doi:10.11843/j.issn.0366-6964.2020.11.018

摘要/Abstract

摘要： 旨在获得产气荚膜梭菌β毒素（CPB）的重组突变体，并评价其毒力及免疫保护性。对已知的产气荚膜梭菌CPB编码基因进行优化设计，同时引入4个氨基酸突变位点，分别是第212位的精氨酸突变为谷氨酸，第268位的亮氨酸突变为甘氨酸，266位的酪氨酸和275位的色氨酸突变为丙氨酸。此外，在该基因5'端添加Th细胞表位（T）和鞭毛蛋白（flagellin）N末端的编码序列，经人工合成获得重组基因片段（GTF_NCPB_m4）。将GTF_NCPB_m4克隆至原核表达载体pET-30a（＋）中进行表达与纯化，获得重组蛋白rTF_NCPB_m4。利用Western blot方法检测rTF_NCPB_m4与C型产气荚膜梭菌毒素抗血清的反应性，并检测rTF_NCPB_m4对小鼠的毒力。随后，以rTF_NCPB_m4免疫家兔，按照《中华人民共和国兽药典》（2015年版）规定的方法检测家兔血清对C型产气荚膜梭菌毒素的中和抗体效价。结果表明，rTF_NCPB_m4主要以包涵体的形式表达且能与C型产气荚膜梭菌毒素抗血清反应。小鼠安全性试验显示，50 μg的rTF_NCPB_m4对小鼠仍无致死性；免疫rTF_NCPB_m4后，每毫升家兔二免抗血清可中和10~20个小鼠最小致死量（MLD）的C型产气荚膜梭菌毒素；1个家兔MLD的C型产气荚膜梭菌毒素攻毒后，对照组家兔4/4死亡，免疫组家兔得到了100%（4/4）的保护。以上结果说明，rTF_NCPB_m4在丧失毒力的同时保留了良好的免疫原性，从而为C型产气荚膜梭菌病基因工程疫苗的研制提供了重要的数据。

关键词: 产气荚膜梭菌CPB, 突变, Th细胞表位, 鞭毛蛋白, 毒力, 免疫保护性

Abstract: This study was conducted to obtain the Clostridium perfringens β toxin (CPB) derivative and to evaluate its virulence and immunoprotection. Based on the known sequence, four amino acid mutations, R212E, L268G, Y266A and W275A, were introduced into the gene of Clostridium perfringens CPB. Meanwhile, genes of Th cell and N-terminal of flagellin were added to 5' of the CPB gene, respectively. Then the gene GTF_NCPB_m4 was optimized and synthesized, and was subsequently cloned into the prokaryotic expression vector pET-30a (＋) for expression and purification to get the recombinant protein, rTF_NCPB_m4. Reactivity of rTF_NCPB_m4with antiserum of Clostridium perfringens type C crude toxins was detected by Western blot. Meanwhile, the toxicity of rTF_NCPB_m4 to mice was evaluated. According to the method prescribed in Chinese Veterinary Pharmacopoeia (2015), rabbits were immunized with rTF_NCPB_m4 to prepare antiserum and detect the neutralizing titer against Clostridium perfringens type C crude toxins. Results showed that rTF_NCPB_m4 was presented predominantly in an insoluble form (inclusion bodies), and it could react with the antiserum of Clostridium perfringens type C crude toxins. rTF_NCPB_m4 with an injection volume of 50 μg was still not fatal to mice. Sera from rabbits immunized with rTF_NCPB_m4can neutralize 10-20 mouse minimum lethal doses (MLD) of Clostridium perfringens type C crude toxins after twice immunization. Moreover, rabbits immunized with rTF_NCPB_m4 can fully resist 1 rabbit MLD of Clostridium perfringens type C crude toxins challenge, whereas all of the rabbits died (4/4) in the control groups. These data suggest that rTF_NCPB_m4 is a potential vaccine candidate for the subunit vaccine of Clostridium perfringens type C.

Key words: Clostridium perfringens CPB, mutation, Th cell epitope, flagellin, virulence, immunoprotection

中图分类号:

S851.616.3

杜吉革, 朱真, 徐中清, 李倩琳, 姚文生, 李启红, 印春生, 杨柳, 付利芝, 陈小云, 刘莹, 薛麒. 重组产气荚膜梭菌β毒素突变体的表达与免疫保护性分析[J]. 畜牧兽医学报, 2020, 51(11): 2794-2801.

DU Jige, ZHU Zhen, XU Zhongqing, LI Qianlin, YAO Wensheng, LI Qihong, YIN Chunsheng, YANG Liu, FU Lizhi, CHEN Xiaoyun, LIU Ying, XUE Qi. Expression and Protective Efficacy of Clostridium perfringens β toxin Derivative[J]. Acta Veterinaria et Zootechnica Sinica, 2020, 51(11): 2794-2801.

参考文献 32

[1]	郑晓丽, 窦贤明, 胡道俊, 等. 产气荚膜梭菌对养牛业的危害及其防制[J]. 中国畜牧兽医, 2010, 37(8):211-214.ZHENG X L, DOU X M, HU D J, et al. The threat, prevention and control of Clostridium perfringens in cattle industry[J]. China Animal Husbandry & Veterinary Medicine, 2010, 37(8):211-214. (in Chinese)
[2]	柳美玲, 王爱华, 陈凤梅, 等. 浅析牛产气荚膜梭菌病[J]. 山东畜牧兽医, 2015(2):59-61.LIU M L, WANG A H, CHEN F M, et al. Clostridium perfringens in cattle industry[J]. Shandong Journal of Animal Science and Veterinary Medicine, 2015(2):59-61. (in Chinese)
[3]	钏有科, 肖啸, 濮永华, 等. 努比亚山羊产气荚膜梭菌病的诊治[J]. 中国兽医杂志, 2014, 50(12):42-43.CHUAN Y K, XIAO X, PU Y H, et al. Diagnosis and treatment of Clostridium perfringens infection in Nubian goats[J]. Chinese Journal of Veterinary Medicine, 2014, 50(12):42-43. (in Chinese)
[4]	郑晓丽, 宋振银, 倪学勤. 产气荚膜梭菌对家禽业的危害及其预防[J]. 中国家禽, 2008, 30(24):69-71.ZHENG X L, SONG Z Y, NI X Q. Emerging threat and prevention of Clostridium perfringens in poultry industry[J]. China Poultry, 2008, 30(24):69-71. (in Chinese)
[5]	LEBRUN M, MAINIL J G, LINDEN A. Cattle enterotoxaemia and Clostridium perfringens:description, diagnosis and prophylaxis[J]. Vet Rec, 2010, 167(1):13-22.
[6]	杜吉革, 王磊, 薛麒, 等. 产气荚膜梭菌α毒素C末端的二拷贝串联表达与免疫原性分析[J]. 中国兽医杂志, 2019, 55(1):7-10.DU J G, WANG L, XUE Q, et al. Expression and Immunogenicity of a tandem fusion protein of two copies of C-terminal of Clostridium perfringens α toxin[J]. Chinese Journal of Veterinary Medicine, 2019, 55(1):7-10. (in Chinese)
[7]	杜吉革, 薛麒, 朱真, 等. 无毒性产气荚膜梭菌ε毒素突变体的表达及免疫保护力评价[J]. 中国农业科学, 2018, 51(11):2206-2215.DU J G, XUE Q, ZHU Z, et al. Expression and evaluation of protective efficacy of no-toxic Clostridium perfringens ε toxin derivative[J]. Scientia Agricultura Sinica, 2018, 51(11):2206-2215. (in Chinese)
[8]	REVITT-MILLS S A, ROOD J I, ADAMS V. Clostridium perfringens extracellular toxins and enzymes:20 and counting[J]. Microbiol Aust, 2015, 36(3):114-117.
[9]	NAGAHAMA M, OCHI S, ODA M, et al. Recent insights into Clostridium perfringens beta-toxin[J]. Toxins, 2015, 7(2):396-406.
[10]	彭小兵, 田冬青, 彭国瑞, 等. 产气荚膜梭菌β毒素的表达及其抗血清的制备[J]. 畜牧与兽医, 2015, 47(10):93-96.PENG X B, TIAN D Q, PENG G R, et al. Expression of Clostridium perfringens β toxin and preparation of its antiserum[J]. Animal Husbandry & Veterinary Medicine, 2015, 47(10):93-96. (in Chinese)
[11]	SALVARANI F M, CONCEIÇÃO F R, CUNHA C E P, et al. Vaccination with recombinant Clostridium perfringens toxoids α and β promotes elevated antepartum and passive humoral immunity in swine[J]. Vaccine, 2013, 31(38):4152-4155.
[12]	MILACH A, DE LOS SANTOS J R G, TURNES C G, et al. Production and characterization of Clostridium perfringens recombinant β toxoid[J]. Anaerobe, 2012, 18(3):363-365.
[13]	MOREIRA G M S G, SALVARANI F M, DA CUNHA C E P, et al. Immunogenicity of a trivalent tecombinant vaccine against Clostridium perfringens alpha, beta, and epsilon toxins in farm ruminants[J]. Sci Rep, 2016, 6(1):22816.
[14]	ZENG J, DENG G C, WANG J, et al. Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows[J]. Vaccine, 2011, 29(33):5459-5466.
[15]	LANGROUDI R P, SHAMSARA M, AGHAIYPOUR K. Expression of Clostridium perfringens epsilon-beta fusion toxin gene in E. coli and its immunologic studies in mouse[J]. Vaccine, 2013, 31(32):3295-3299.
[16]	NAGAHAMA M, KIHARA A, MIYAWAKI T, et al. Clostridium perfringens β-toxin is sensitive to thiol-group modification but does not require a thiol group for lethal activity[J]. Biochim Biophys Acta, 1999, 1454(1):97-105.
[17]	STEINTHORSDOTTIR V, FRIDRIKSDOTTIR V, GUNNARSSON E, et al. Site-directed mutagenesis of Clostridium perfringens beta-toxin:expression of wild-type and mutant toxins in Bacillus subtilis[J]. FEMS Microbiol Lett, 1998, 158(1):17-23.
[18]	马鸣潇, 金宁一, 尹革芬, 等. 口蹄疫病毒三价复合多表位佐剂DNA疫苗构建及其免疫原性[J]. 生物工程学报, 2009, 25(4):514-519.MA M X, JIN N Y, YIN G F, et al. Molecular design and immunogenicity of a multiple-epitope foot-and-mouth disease virus antigen, adjuvants, and DNA vaccination[J]. Chinese Journal of Biotechnology, 2009, 25(4):514-519. (in Chinese)
[19]	孙小涵, 张碧成, 张强, 等. 非致病性大肠杆菌鞭毛蛋白对O型口蹄疫病毒的佐剂效果[J]. 中国农业科学, 2017, 50(9):1714-1722.SUN X H, ZHANG B C, ZHANG Q, et al. Adjuvant effects of flagellin from non-pathogenic E.coli on FMDV[J]. Scientia Agricultura Sinica, 2017, 50(9):1714-1722. (in Chinese)
[20]	陈小云, 刘莹, 薛麒, 等. 重组腐败梭菌α毒素对兔的免疫效力分析[J]. 畜牧兽医学报, 2018, 49(8):1727-1734.CHEN X Y, LIU Y, XUE Q, et al. Evaluation of protective efficacy of recombinant Clostridium septicum α toxin in rabbits[J] Acta Veterinaria et Zootechnica Sinica, 2018, 49(8):1727-1734. (in Chinese)
[21]	杜吉革, 张秀坤, 朱真, 等. 重组产气荚膜梭菌ε毒素三点突变体的融合表达及其免疫活性分析[J]. 中国兽药杂志, 2018, 52(7):28-34.DU J G, ZHANG X K, ZHU Z, et al. Expression and immunocompetence of Clostridium perfringens ε toxin derivative with three mutations[J]. Chinese Journal of Veterinary Drug, 2018, 52(7):28-34. (in Chinese)
[22]	LI J H, ADAMS V, BANNAM T L, et al. Toxin plasmids of Clostridium perfringens[J]. Microbiol Mol Biol Rev, 2013, 77(2):208-223.
[23]	杜吉革, 彭小兵, 张秀坤, 等. 产气荚膜梭菌ε毒素突变体的表达及免疫保护力评价[J]. 中国兽药杂志, 2018, 52(6):13-20.DU J G, PENG X B, ZHANG X K, et al. Expression and evaluation of protective efficacy of Clostridium perfringens ε toxin mutant[J]. Chinese Journal of Veterinary Drug, 2018, 52(6):13-20. (in Chinese)
[24]	ALIMOLAEI M, GOLCHIN M, DANESHVAR H. Oral immunization of mice against Clostridium perfringens epsilon toxin with a Lactobacillus casei vector vaccine expressing epsilon toxoid[J]. Infect Genet Evol, 2016, 40:282-287.
[25]	LI Q, XIN W W, GAO S, et al. A low-toxic site-directed mutant of Clostridium perfringens ε -toxin as a potential candidate vaccine against enterotoxemia[J]. Hum Vaccin Immunother, 2013, 9(11):2386-2392.
[26]	YAO W W, KANG J J, KANG L, et al. Immunization with a novel Clostridium perfringens epsilon toxin mutant rETXY196E-C confers strong protection in mice[J]. Sci Rep, 2016, 6(1):24162.
[27]	VERHERSTRAETEN S, GOOSSENS E, VALGAEREN B, et al. Non-toxic perfringolysin O and α-toxin derivatives as potential vaccine candidates against bovine necrohaemorrhagic enteritis[J]. Vet J, 2016, 217:89-94.
[28]	NAGAHAMA M, ODA M, KOBAYASHI K, et al. A recombinant carboxy-terminal domain of alpha-toxin protects mice against Clostridium perfringens[J]. Microbiol Immunol, 2013, 57(5):340-345.
[29]	DAS S, MAJUMDER S, KINGSTON J J, et al. Generation and characterization of recombinant bivalent fusion protein r-Cpib for immunotherapy against Clostridium perfringens beta and iota toxemia[J]. Mol Immunol, 2016, 70:140-148.
[30]	BHATIA B, SOLANKI A K, KAUSHIK H, et al. B-cell epitope of beta toxin of Clostridium perfringens genetically conjugated to a carrier protein:expression, purification and characterization of the chimeric protein[J]. Protein Exp Purif, 2014, 102(10):38-44.
[31]	HU J F, CLADEL N M, CHRISTENSEN N D. Increased immunity to cottontail rabbit papillomavirus infection in EIII/JC inbred rabbits after vaccination with a mutant E6 that correlates with spontaneous regression[J]. Viral Immunol, 2007, 20(2):320-325.
[32]	YANG Y L, MENG B, HUANG Z H. PP-099 Hepatitis B surface antigen mutation Thr to Met at position 118 leads to antigenicity change and causes some blood screening kits failure[J]. Int J Infect Dis, 2009, 13(S1):S75-S76.